Skip to main content
    G

    Gelteq Limited Ordinary Shares (GELS)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.44
    -0.01 (-2.38%)

    Market Cap: $4.82M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    PeriodReportedEst.SurpriseB/MYoY
    Sep 25
    Reported Nov 17
    		$-0.34$0.00N/AMiss-
    Mar 25
    Reported Jun 30
    		$-0.38$0.00N/AMiss-
    Sep 24
    Reported Nov 15
    		$-0.14$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-1985.00%
    ROE-42.90%ROICN/A
    Financial Health
    Debt/Equity0.36xInterest CoverageN/A
    Current Ratio0.09xQuick Ratio0.09x
    Trading Statistics
    BetaN/AAvg Volume1.62M
    52-Week High$2.0152-Week Low$0.39

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.51
    SMA 20$0.54
    SMA 50$0.59
    SMA 200$0.68
    EMA 10$0.50
    EMA 20$0.53
    EMA 50$0.58
    EMA 200$0.72

    MACD

    Line: -0.04Signal: -0.03Hist: -0.01

    ADX

    ADX: 35.7+DI: 25.4-DI: 20.0

    Aroon & PSAR

    Aroon Up32.0
    Aroon Down100.0
    PSAR$0.58

    Bollinger Bands

    Upper Band$0.62
    Lower Band$0.45
    %B Position3298%(Upper)
    Band Width-0.05

    RSI (14-Day)

    Neutral
    34.7

    Momentum Oscillators

    Stoch %K4.1
    Stoch %D6.8
    Williams %R-93.7
    ROC (10d)-19.0%
    Momentum-0.10
    CCI (20d)-216.8
    MFI (14d)45.1

    Volatility Measures

    ATR (14d)$0.06(14.7%)
    StdDev (20d)0.04
    Hist Vol64.8%(High)

    Volume Flow

    VWAP$0.44
    OBV728.7M
    AD Line-12.2M
    CMF (20d)-0.299

    Volume Metrics

    Avg Vol (20d)1.8M
    Vol Ratio0.0x(Low)
    VWMA (20d)$0.61

    Pivot Points

    R3$0.50
    R2$0.49
    R1$0.47
    Pivot Point$0.46
    S1$0.44
    S2$0.43
    S3$0.41

    Advanced Oscillators

    TSI-17.00
    Ultimate Osc28.6
    KST-151.55

    Financial Data

    QuarterMar 2026Sep 2025Sep 2024Jun 2024Mar 2024Jun 2023Jun 2022Jun 2021
    Total Revenue$89,296$89,296N/A$0$0$-1$147,536N/A
    Cost of RevenueN/AN/AN/A$0N/A$0N/AN/A
    Gross Profit$89,296$89,296N/A$0N/A$-1$147,536N/A
    Operating Expenses$1.86M$1.86M$966,555$911,620$10.10M$833,354$1.19M$391,986
    R&D$192,364$192,364$88,231$88,231$86,892$234,479$210,551$54,947
    SG&A$734,683$734,683$560,332$550,352$14,246$705,442$1.07M$144,420
    Operating Income$-1,773,452$-1,773,452$-966,555$-911,620$-10,097,495$-833,355$-1,041,456N/A
    Interest Income$0$0$0$0$0$0$0$0
    Interest Expense$451,036$451,036$151,477$151,477$146,852$113,338$100,979$1,297
    Income Before Tax$-1,871,052$-1,871,052$-1,133,132$-1,133,132$-727,419$-947,830$-1,236,660$-393,283
    Income Tax Expense$0$0$0$0$0$0$0$-159,869
    Net Income$-1,871,052$-1,871,052$-1,133,132$-1,133,132$-727,419$-947,830$-1,236,660$-233,414
    EBITDA$-1,462,284$-1,462,284$-683,628N/A$-279,744$-527,688$-829,366$-335,831
    EBIT$-1,772,778$-1,772,778$-981,655N/A$-580,567$-834,492$-1,135,681$-391,986
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GELS

    News

    Could Gelteq’s (GELS) Gel Improve Oral Drug Delivery?

    Gelteq (GELS) is an Australian biotechnology company developing a proprietary gel-based delivery platform to improve oral drug delivery. Preclinical results show increased bioavailability and faster absorption...

    Simply Wall Street•10/9/26•Somewhat-Bullish

    Could Gelteq’s (GELS) Gel Improve Oral Drug Delivery?

    Gelteq (GELS), an Australian biotechnology company, is developing a proprietary gel-based drug delivery platform that aims to improve oral drug administration by enhancing bioavailability, absorption...

    Yahoo Finance Singapore•10/9/26•Bullish

    Nasdaq Gains Over 200 Points; US Weekly Jobless Claims Edge Higher

    U.S. stocks saw broad gains, with the Nasdaq Composite rising over 200 points, despite a slight increase in weekly jobless claims to 206,000. Several companies experienced significant stock movements...

    Benzinga•9/3/26•Bullish

    Gelteq Ltd (GELS) Earnings Forecast: Future EPS & Revenue Growth Estimates

    This article provides an earnings forecast for Gelteq Ltd (GELS), focusing on future EPS and revenue growth estimates. It includes current stock performance, market capitalization...

    TradingKey•8/6/26•Neutral

    Gelteq Ltd (GELS) Valuation: PE, PB & Fair Value Analysis

    This article provides a brief valuation analysis for Gelteq Ltd (GELS), focusing on its stock performance and key financial ratios like P/E, P/B...

    TradingKey•7/27/26•Neutral

    GELS Valuation and Fair Value

    P/B
    0.3x
    See GNG's fair value

    GELS Profitability: Margins, ROIC and FCF

    Operating margin
    -1985.0%
    Net margin
    0.0%
    ROE
    -42.9%

    GELS Competitors

    CompanyTicker
    Xenetic Biosciences IncXBIO
    Intelligent Bio Solutions Inc.INBS
    Cardio Diagnostics Holdings IncCDIO
    XTL Biopharmaceuticals Ltd ADRXTLB
    Kala Pharmaceuticals IncKALA
    Redhill Biopharma LtdRDHL
    Biomx IncPHGE
    bioAffinity Technologies, Inc.BIAF

    Sector: Healthcare

    GELS Bull Case vs Bear Case

    Bull case

    • GELS grew quarterly revenue 48.9% year over year.

    Frequently Asked Questions About GELS

    Does GELS pay dividends?

    Gelteq Limited Ordinary Shares (GELS) does not currently pay a regular dividend.

    What is GELS's market cap?

    Gelteq Limited Ordinary Shares (GELS) has a market capitalization of $4.82M with a current stock price of $0.44.

    Related stocks

    Sector: Healthcare

    All stocks starting with G

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In